

WHO Expert Committee on Drug Dependence

Fortieth report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order online: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 1 3

WHO Expert Committee on Drug Dependence

Fortieth report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Expert Committee on Drug Dependence: Fortieth report

(WHO Technical Report Series, No. 1013)

ISBN 978-92-4-121022-5

ISSN 0512-3054

©World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Drug Dependence, fortieth report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1013).. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed in France.

Contents

WHO Expert Committee on Drug Dependence	vi
Members	vi
Temporary advisers	vi
Representatives of other organizations	vii
WHO Secretariat (WHO Headquarters, Geneva, Switzerland)	vii
Abbreviations	viii
1. Introduction	1
Declarations of interest	3
2. WHO Expert Committee on Drug Dependence (ECDD): review procedures and processes	5
2.1 Pre-reviews and critical reviews	5
2.2 Member State questionnaires	5
3. Open session	6
4. Briefings from international organizations on their work on the public health dimension of the world drug problem	8
4.1 Update from the international Narcotics Control Board	8
4.2 Update from the United Nations Office on Drugs and Crime	9
4.3 Update from the World Health Organization	10
5. Review of substances	12
6. Cannabidiol	13
6.1 Substance identification	13
6.2 Chemistry	13
6.3 Ease of convertibility into controlled substances	13
6.4 General pharmacology	13
6.5 Toxicology	14
6.6 Adverse reactions in humans	14
6.7 Dependence potential	14
6.8 Abuse potential	14
6.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	15
6.10 Listing in the WHO Model List of Essential Medicines	15
6.11 Marketing authorizations (as a medicinal product)	16
6.12 Industrial use	16
6.13 Non-medical use, abuse and dependence	16
6.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	16
6.15 Licit production, consumption and international trade	16
6.16 Illicit manufacture and traffic and related information	16
6.17 Current international controls and their impact	16
6.18 Current and past national controls	17
6.19 WHO review history	17
6.20 Recommendation	17

7. Cannabis and cannabis resin	18
7.1 Substance identification	18
7.2 Chemistry	18
7.3 Ease of convertibility into controlled substances	19
7.4 General pharmacology	19
7.5 Toxicology	20
7.6 Adverse reactions in humans	20
7.7 Dependence potential	21
7.8 Abuse potential	21
7.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	22
7.10 Listing on the WHO Model List of Essential Medicines	22
7.11 Marketing authorizations (as a medicinal product)	22
7.12 Industrial use	22
7.13 Non-medical use, abuse and dependence	22
7.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	23
7.15 Licit production, consumption and international trade	23
7.16 Illicit manufacture and traffic and related information	23
7.17 Current international controls and their impact	23
7.18 Current and past national controls	23
7.19 WHO review history	23
7.20 Recommendation	24
8. Extracts and tinctures of cannabis	25
8.1 Substance identification	25
8.2 Chemistry	25
8.3 Ease of convertibility into controlled substances	27
8.4 General pharmacology	27
8.5 Toxicology	28
8.6 Adverse reactions in humans	28
8.7 Dependence potential	29
8.8 Abuse potential	29
8.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	29
8.10 Listing on the WHO Model List of Essential Medicines	30
8.11 Marketing authorizations (as a medicinal product)	30
8.12 Industrial use	30
8.13 Non-medical use, abuse and dependence	30
8.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	30
8.15 Licit production, consumption and international trade	30
8.16 Illicit manufacture and traffic and related information	31
8.17 Current international controls and their impact	31
8.18 Current and past national controls	31
8.19 WHO review history	31
8.20 Recommendation	31
9. Delta-9-tetrahydrocannabinol (Δ^9-THC; dronabinol)	33
9.1 Substance identification	33

9.2	Chemistry	33
9.3	Ease of convertibility into controlled substances	33
9.4	General pharmacology	34
9.5	Toxicology	35
9.6	Adverse reactions in humans	35
9.7	Dependence potential	36
9.8	Abuse potential	36
9.9	Therapeutic applications and extent of therapeutic use and epidemiology of medical use	37
9.10	Listing on the WHO Model List of Essential Medicines	37
9.11	Marketing authorizations (as a medicinal product)	37
9.12	Industrial use	37
9.13	Non-medical use, abuse and dependence	38
9.14	Nature and magnitude of public health problems related to misuse, abuse and dependence	38
9.15	Licit production, consumption and international trade	38
9.16	Illicit manufacture and traffic and related information	38
9.17	Current international controls and their impact	38
9.18	Current and past national controls	38
9.19	WHO review history	38
9.20	Recommendation	40
10.	Tetrahydrocannabinol (Isomers of THC)	42
10.1	Substance identification	42
10.2	Chemistry	42
10.3	Ease of convertibility into controlled substances	42
10.4	General pharmacology	42
10.5	Toxicology	43
10.7	Dependence potential	43
10.8	Abuse potential	43
10.9	Therapeutic applications, extent of therapeutic use and epidemiology of medical use	44
10.10	Listing in the WHO Model List of Essential Medicines	44
10.11	Marketing authorizations (as a medicinal product)	44
10.12	Industrial use	44
10.13	Non-medical use, abuse and dependence	44
10.14	Nature and magnitude of public health problems related to misuse, abuse and dependence	44
10.15	Licit production, consumption and international trade	45
10.16	Illicit manufacture and traffic and related information	45
10.17	Current international controls and their impact	45
10.18	Current and past national controls	45
10.19	WHO review history	45
10.20	Recommendation	45
11.	Summary	46
	Acknowledgements	47
	References	48

WHO Expert Committee on Drug Dependence

Geneva, Switzerland, 4–7 June 2018

Members

Professor Patrick M. Beardsley, Professor of Pharmacology and Toxicology, Institute for Drug and Alcohol Studies, and Centre for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, United States of America (Rapporteur)

Professor Bruna Brands, Professor of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Canada (Chair)

Dr Ifeoma Toyin Ekwere, Senior Consultant Anaesthesiologist, University of Benin Teaching Hospital, Benin City, Nigeria

Dr Simon Elliott, Consultant Forensic Toxicologist and Managing Director of Alere Forensics, England

Professor Katia Gysling, Professor at the Faculty of Biological Sciences, Center for Addiction Studies, Pontificia Universidad Catolica de Chile, Republic of Chile

Professor Raka Jain, Professor of Chemistry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India

Dr Pamela Kaduri, Assistant Professor, Department of Psychiatry, University of Toronto and adjunct faculty, Muhimbili University of Health and Allied Sciences, United Republic of Tanzania

Dr Junichi Kitanaka, Associate Professor, Department of Pharmacology, Hyogo College of Medicine, Japan

Dr Afarin Rahimi-Movaghar, Professor of Psychiatry, Director of Iranian National Centre for Addiction Studies, Tehran University of Medical Sciences, Islamic Republic of Iran

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25919

